Your browser doesn't support javascript.
Effectiveness of early treatment of lopinavir-ritonavir in patients with severe COVID-19: a case series.
Luo, Pan; Zheng, Jian-Ling; Liu, Yi; Qiu, Lin; Liu, Xiu-Lan; Xue, Hui-Ying; Liu, Dong; Li, Juan.
  • Luo P; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Zheng JL; joint first authors.
  • Liu Y; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Qiu L; joint first authors.
  • Liu XL; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Xue HY; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Liu D; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Li J; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Clin Med (Lond) ; 21(1): e80-e83, 2021 Jan.
Article in English | MEDLINE | ID: covidwho-1000587
ABSTRACT

AIM:

The inconsistent effects of lopinavir-ritonavir (LPV/r) on COVID-19 seem to be caused by the therapeutic window. In the present study, we aim to present the effects of early LPV/r treatment on patients with severe COVID-19.

METHODS:

The demographics, characteristics, treatments, SARS-CoV-2 test results and outcomes of 19 patients with severe COVID-19 treated with LPV/r within 12 days of onset of symptoms were retrospectively assessed.

RESULTS:

Within 3 days of admission, three (15.79%) patients received noninvasive ventilation, and 16 (84.21%) patients received high-flow oxygen support. The median duration between the onset of symptoms and initiating LPV/r therapy was 9 (range 2-12) days. The median course of LPV/r treatment was 11 (range 7-17) days. One of the 19 patients (5.26%) died. Of the 18 patients discharged, the median hospital stay was 17 (range 11-45) days. At day 6 after LPV/r therapy was initiated, 68.42% of patients were virologically cured, increasing to 84.22% at day 12.

CONCLUSION:

In this cohort of patients with severe COVID-19 who were treated with LPV/r within 12 days of the onset of symptoms, clinical improvement was observed in 18/19 patients (94.74%). Randomised controlled trials are urgently needed to further evaluate this strategy.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Ritonavir / Lopinavir / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Clin Med (Lond) Year: 2021 Document Type: Article Affiliation country: Clinmed.2020-0348

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Ritonavir / Lopinavir / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Clin Med (Lond) Year: 2021 Document Type: Article Affiliation country: Clinmed.2020-0348